Background: Cervical and breast cancers are leading causes of death among women. Although many current treatments used to treat these diseases, it is still rapidly spreading worldwide. Recently, triazole compounds have shown their ability to eliminate cancer. Aim: This study aims to investigate the anticancer properties of newly synthesized Triazoles (14a) against cervical and breast cancer cell lines. Methods: The cytotoxic effects of the triazole compound (14a) on cervical and breast cancer cell lines (Hela and MCF-7, respectively) were determined using MTT assay. Anti-viability properties examined using trypan blue, clonogenic assay. The ability of the compound to inhibit cancer cell migration was tested by scratch assays. To understand the mechanism of action of compound 14a, key apoptotic and cell cycle proteins were determined using the western blotting. Results: Our results show that triazole 14a has a cytotoxic effect on both HeLa and MCF-7 cells with IC50s of 54.6μM and 110µM, respectively. The results of the trypan blue test show that 60µM of triazole 14a kills about 85% of HeLa cells after 48 hours of the treatment. However, treatment with 14a at 60μM and 100μM for 48 hours kills around 10% and 30% of MCF-7 cells respectively. In addition, triazole 14a inhibits the ability of cervical cancer cells to migrate in vitro. Clonogenic survival assay shows that 60μM of 14a decreases Hela survival rate by more than 90%. The extrinsic apoptosis and cell cycle arrest are induced by 14a treatment. This is evident by the increased level of cell cycle arrest proteins cyclin D1, P53, and P21 and apoptotic marker cleaved PARP. Conclusion: A newly synthesized triazole (14a) is a promising compound against cervical and breast cancer cells.